348 related articles for article (PubMed ID: 19254516)
1. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.
Szegedi A; Jansen WT; van Willigenburg AP; van der Meulen E; Stassen HH; Thase ME
J Clin Psychiatry; 2009 Mar; 70(3):344-53. PubMed ID: 19254516
[TBL] [Abstract][Full Text] [Related]
2. Early Improvements in Individual Symptoms to Predict Later Remission in Major Depressive Disorder Treated With Mirtazapine.
Funaki K; Nakajima S; Suzuki T; Mimura M; Uchida H
J Clin Pharmacol; 2016 Sep; 56(9):1111-9. PubMed ID: 26813241
[TBL] [Abstract][Full Text] [Related]
3. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
Blier P; Ward HE; Tremblay P; Laberge L; Hébert C; Bergeron R
Am J Psychiatry; 2010 Mar; 167(3):281-8. PubMed ID: 20008946
[TBL] [Abstract][Full Text] [Related]
4. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
[TBL] [Abstract][Full Text] [Related]
5. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
6. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
7. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.
Szegedi A; Müller MJ; Anghelescu I; Klawe C; Kohnen R; Benkert O
J Clin Psychiatry; 2003 Apr; 64(4):413-20. PubMed ID: 12716243
[TBL] [Abstract][Full Text] [Related]
8. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
[TBL] [Abstract][Full Text] [Related]
9. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
Chekroud AM; Gueorguieva R; Krumholz HM; Trivedi MH; Krystal JH; McCarthy G
JAMA Psychiatry; 2017 Apr; 74(4):370-378. PubMed ID: 28241180
[TBL] [Abstract][Full Text] [Related]
10. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.
McGrath PJ; Stewart JW; Fava M; Trivedi MH; Wisniewski SR; Nierenberg AA; Thase ME; Davis L; Biggs MM; Shores-Wilson K; Luther JF; Niederehe G; Warden D; Rush AJ
Am J Psychiatry; 2006 Sep; 163(9):1531-41; quiz 1666. PubMed ID: 16946177
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
Fawcett J; Barkin RL
J Clin Psychiatry; 1998 Mar; 59(3):123-7. PubMed ID: 9541155
[TBL] [Abstract][Full Text] [Related]
12. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial.
Hummel J; Westphal S; Weber-Hamann B; Gilles M; Lederbogen F; Angermeier T; Luley C; Deuschle M; Kopf D
J Clin Psychiatry; 2011 Jul; 72(7):885-91. PubMed ID: 21294998
[TBL] [Abstract][Full Text] [Related]
13. Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT.
Kato M; Takekita Y; Koshikawa Y; Sakai S; Bandou H; Nishida K; Sunada N; Onohara A; Hatashita Y; Serretti A; Kinoshita T
J Psychiatr Res; 2017 Jun; 89():97-104. PubMed ID: 28213170
[TBL] [Abstract][Full Text] [Related]
14. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.
Fava M; Rush AJ; Wisniewski SR; Nierenberg AA; Alpert JE; McGrath PJ; Thase ME; Warden D; Biggs M; Luther JF; Niederehe G; Ritz L; Trivedi MH
Am J Psychiatry; 2006 Jul; 163(7):1161-72. PubMed ID: 16816220
[TBL] [Abstract][Full Text] [Related]
15. Mirtazapine compared with paroxetine in major depression.
Benkert O; Szegedi A; Kohnen R
J Clin Psychiatry; 2000 Sep; 61(9):656-63. PubMed ID: 11030486
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy.
Kornstein SG; Dunner DL; Meyers AL; Whitmyer VG; Mallinckrodt CH; Wohlreich MM; Detke MJ; Hollandbeck MS; Greist JH
J Clin Psychiatry; 2008 Sep; 69(9):1383-92. PubMed ID: 19193339
[TBL] [Abstract][Full Text] [Related]
17. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
[TBL] [Abstract][Full Text] [Related]
18. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
19. [Antidepressants and their onset of action: a major clinical, methodological and pronostical issue].
Gourion D
Encephale; 2008 Jan; 34(1):73-81. PubMed ID: 18514154
[TBL] [Abstract][Full Text] [Related]
20. Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study.
Ng CG; Boks MP; Roes KC; Zainal NZ; Sulaiman AH; Tan SB; de Wit NJ
Eur Neuropsychopharmacol; 2014 Apr; 24(4):491-8. PubMed ID: 24503279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
